TY - JOUR
T1 - Differential RNA aptamer affinity profiling on plasma as a potential diagnostic tool for bladder cancer
AU - Fjelstrup, Søren
AU - Dupont, Daniel M
AU - Bus, Claus
AU - Enghild, Jan J
AU - Jensen, Jørgen B
AU - Birkenkamp-Demtröder, Karin
AU - Dyrskjøt, Lars
AU - Kjems, Jørgen
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of NAR Cancer.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - The molecular composition of blood is a signature of human health, reflected in the thousands of blood biomarkers known for human diseases. However, establishing robust disease markers is challenging due to the diversity of individual samples. New sequencing methods have simplified biomarker discovery for circulating DNA and RNA while protein profiling is still laborious and costly. To harness the power of high-throughput sequencing to profile the protein content of a biological sample, we developed a method termed APTASHAPE that uses oligonucleotide aptamers to recognize proteins in complex biofluids. We selected a large pool of 2'Fluoro protected RNA sequences to recognize proteins in human plasma and identified a set of 33 cancer-specific aptamers. Differential enrichment of these aptamers after selection against 1 μl of plasma from individual patients allowed us to differentiate between healthy controls and bladder cancer-diagnosed patients (91% accuracy) and between early non-invasive tumors and late stage tumors (83% accuracy). Affinity purification and mass spectrometry of proteins bound to the predictive aptamers showed the main target proteins to be C4b-binding protein, Complement C3, Fibrinogen, Complement factor H and IgG. The APTASHAPE method thus provides a general, automated and highly sensitive platform for discovering potential new disease biomarkers.
AB - The molecular composition of blood is a signature of human health, reflected in the thousands of blood biomarkers known for human diseases. However, establishing robust disease markers is challenging due to the diversity of individual samples. New sequencing methods have simplified biomarker discovery for circulating DNA and RNA while protein profiling is still laborious and costly. To harness the power of high-throughput sequencing to profile the protein content of a biological sample, we developed a method termed APTASHAPE that uses oligonucleotide aptamers to recognize proteins in complex biofluids. We selected a large pool of 2'Fluoro protected RNA sequences to recognize proteins in human plasma and identified a set of 33 cancer-specific aptamers. Differential enrichment of these aptamers after selection against 1 μl of plasma from individual patients allowed us to differentiate between healthy controls and bladder cancer-diagnosed patients (91% accuracy) and between early non-invasive tumors and late stage tumors (83% accuracy). Affinity purification and mass spectrometry of proteins bound to the predictive aptamers showed the main target proteins to be C4b-binding protein, Complement C3, Fibrinogen, Complement factor H and IgG. The APTASHAPE method thus provides a general, automated and highly sensitive platform for discovering potential new disease biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=85141326051&partnerID=8YFLogxK
U2 - 10.1093/narcan/zcac025
DO - 10.1093/narcan/zcac025
M3 - Journal article
C2 - 36004048
SN - 2632-8674
VL - 4
JO - NAR cancer
JF - NAR cancer
IS - 3
M1 - zcac025
ER -